CD79A and COVID-19: In a cohort of 361 COVID-19 patients evaluated for aPL in the first days of infection and reevaluated in a second sample after more than 12 weeks, Gil-Etayo et al. found no significant differences in the aPL prevalence between the first and the second samples and found a strong agreement between both determinations for criteria aPL (Weighted kappa: 0.85) and for IgA aB2GP1 antibodies (Weighted kappa: 0.91).